

GENEMEDI

Innovation In Gene Therapy & Biologics

Bispecific antibodies

formats, applications and products for Bone metabolism testing

Bispecific antibodies Catalog

1. Peplines of bispecific antibodies (BsAbs)

Bridge of 2 cells (engagers)

By binding with 2 antigens from 2 different cells, the BsAbs can physically link them together, thus these kinds of BsAbs are named “engagers”. The redirecting of immune cells to tumor cells by the engagers makes the immune cell activated and then eliminate the target cells. The T cell engagers are the most popular BsAbs which account for nearly half of the clinical trials aimed evaluating the BsAbs. NK cell engagers are recently developed BsAbs for NK cell-dependent tumor cell elimination.

The engagers in research, clinical trials and market are listed below. Genemedi offers the high quality, premade benchmark BsAbs for researchers.

Cat No.	Products Name (INN Index)	INN name	Target
GMP-Bios-ab-006	Anti-FOLH1;CD3E therapeutic antibody (Pre-made Acapatamab biosimilar,Bispecific scFv)	Acapatamab	FOLH1;CD3E
GMP-Bios-ab-018	Anti-TNFRSF17;CD3E therapeutic antibody (Pre-made Alnuctamab biosimilar,Bispecific mAb with Domain Crossover)	Alnuctamab	TNFRSF17;CD3E
GMP-Bios-ab-074	Anti-CD19;CD3E therapeutic antibody (Pre-made Blinatumomab biosimilar,Bispecific T-Cell Engager)	Blinatumomab	CD19;CD3E
GMP-Bios-ab-103	Anti-FCRL5;CD3 therapeutic antibody (Pre-made Cevostamab biosimilar,Bispecific mAb)	Cevostamab	FCRL5;CD3
GMP-Bios-ab-104	Anti-CEACAM5&CD3E;CD3E therapeutic antibody (Pre-made Cibisatamab biosimilar,Bispecific mAb with Domain Crossover)	Cibisatamab	CEACAM5& CD3E;CD3E
GMP-Bios-ab-161	Anti-CD19;CD3E therapeutic antibody (Pre-made Duvortuxizumab biosimilar,Bispecific scFv with Crossover)	Duvortuxizumab	CD19;CD3E
GMP-Bios-ab-173	Anti-CD33;CD3E therapeutic antibody (Pre-made Eluvixtamab biosimilar,Bispecific scFv)	Eluvixtamab	CD33;CD3E
GMP-Bios-ab-176	Anti-CD33;CD3E therapeutic antibody (Pre-made Emerfetamab biosimilar,Bispecific scFv)	Emerfetamab	CD33;CD3E

Cat No.	Products Name (INN Index)	INN name	Target
GMP-Bios-ab-189	Anti-CD3E;MS4A1 therapeutic antibody (Pre-made Epcoritamab biosimilar,Bispecific mAb)	Epcoritamab	CD3E;MS4A1
GMP-Bios-ab-197	Anti-EGFR;CD3E therapeutic antibody (Pre-made Etevritamab biosimilar,Bispecific scFv)	Etevritamab	EGFR;CD3E
GMP-Bios-ab-218	Anti-IL3RA;CD3E therapeutic antibody (Pre-made Flotetuzumab biosimilar,Bispecific scFv with Crossover)	Flotetuzumab	IL3RA;CD3E
GMP-Bios-ab-248	Anti-CD3E;MS4A1 therapeutic antibody (Pre-made Glofitamab biosimilar,Bispecific mAb with Domain Crossover)	Glofitamab	CD3E;MS4A1
GMP-Bios-ab-356	Anti-CD3E;MS4A1 therapeutic antibody (Pre-made Mosunetuzumab biosimilar,Bispecific mAb)	Mosunetuzumab	CD3E;MS4A1
GMP-Bios-ab-380	Anti-GD2;CD3E therapeutic antibody (Pre-made Nivatrotamab biosimilar,Bispecific Mixed mAb and scFv)	Nivatrotamab	GD2;CD3E
GMP-Bios-ab-386	Anti-CD276;CD3E therapeutic antibody (Pre-made Obrindatamab biosimilar,Bispecific scFv with Domain Crossover)	Obrindatamab	CD276;CD3E
GMP-Bios-ab-391	Anti-MS4A1;CD3E therapeutic antibody (Pre-made Odronextamab biosimilar,Bispecific mAb)	Odronextamab	MS4A1;CD3E
GMP-Bios-ab-421	Anti-TNFRSF17;CD3E therapeutic antibody (Pre-made Pacanalotamab biosimilar,Bispecific scFv)	Pacanalotamab	TNFRSF17;CD3E
GMP-Bios-ab-429	Anti-FOLH1;CD3E therapeutic antibody (Pre-made Pasotuxizumab biosimilar,Bispecific scFv)	Pasotuxizumab	FOLH1;CD3E
GMP-Bios-ab-433	Anti-TNFRSF17;CD3E therapeutic antibody (Pre-made Pavurutamab biosimilar,Bispecific scFv)	Pavurutamab	TNFRSF17;CD3E
GMP-Bios-ab-446	Anti-MS4A1;CD3E therapeutic antibody (Pre-made Plamotamab biosimilar,Bispecific Mixed mAb and scFv)	Plamotamab	MS4A1;CD3E

Cat No.	Products Name (INN Index)	INN name	Target
GMP-Bios-ab-500	Anti-ERBB2;CD3E therapeutic antibody (Pre-made Runimotamab biosimilar,Bispecific mAb)	Runimotamab	ERBB2;CD3E
GMP-Bios-ab-528	Anti-EPCAM;CD3E therapeutic antibody (Pre-made Solitomab biosimilar,Bispecific scFv)	Solitomab	EPCAM;CD3E
GMP-Bios-ab-546	Anti-GPRC5D;CD3E therapeutic antibody (Pre-made Talquetamab biosimilar,Bispecific mAb)	Talquetamab	GPRC5D;CD3E
GMP-Bios-ab-552	Anti-DLL3;CD3E therapeutic antibody (Pre-made Tarlatamab biosimilar,Bispecific scFv)	Tarlatamab	DLL3;CD3E
GMP-Bios-ab-557	Anti-TNFRSF17;CD3E therapeutic antibody (Pre-made Teclistamab biosimilar,Bispecific mAb)	Teclistamab	TNFRSF17;CD3E
GMP-Bios-ab-563	Anti-CLEC12A;CD3E therapeutic antibody (Pre-made Tepoditamab biosimilar,Bispecific mAb)	Tepoditamab	CLEC12A;CD3E
GMP-Bios-ab-570	Anti-SSTR2;CD3E therapeutic antibody (Pre-made Tidutamab biosimilar,Bispecific Mixed mAb and scFv)	Tidutamab	SSTR2;CD3E
GMP-Bios-ab-619	Anti-IL3RA;CD3E therapeutic antibody (Pre-made Vibecotamab biosimilar,Bispecific Mixed mAb and scFv)	Vibecotamab	IL3RA;CD3E
GMP-Bios-ab-624	Anti-CD3E;CD33 therapeutic antibody (Pre-made Vixtimotamab biosimilar,Bispecific Homodimer (VK-VH-VL'-VH', Tandem diabody))	Vixtimotamab	CD3E;CD33
GMP-Bios-ab-663	Anti-TNFRSF17;CD3E therapeutic antibody (Pre-made Elranatamab biosimilar,Whole mAb)	Elranatamab	TNFRSF17;CD3E
GMP-Bios-ab-670	Anti-CLDN18;CD3E therapeutic antibody (Pre-made Gresonitamab biosimilar,Whole mAb)	Gresonitamab	CLDN18;CD3E
GMP-Bios-ab-673	Anti-CD37;CD37 therapeutic antibody (Pre-made Ivicentamab biosimilar,Whole mAb)	Ivicentamab	CD37;CD37

Cat No.	Products Name (INN Index)	INN name	Target
GMP-Bios-ab-705	Anti-MUC16;CD3E therapeutic antibody (Pre-made Ubamatamab biosimilar,Whole mAb)	Ubamatamab	MUC16;CD3E
GMP-Bios-ab-708	Anti-MUC17;CD3E therapeutic antibody (Pre-made Vepsitamab biosimilar,Whole mAb)	Vepsitamab	MUC17;CD3E
GMP-Bios-ab-709	Anti-FOLH1;CD3E therapeutic antibody (Pre-made Voxalatamab biosimilar,Whole mAb)	Voxalatamab	FOLH1;CD3E
GMP-Bios-INN-772	Anti-EpCAM;CD3E therapeutic antibody (Pre-made Catumaxomab biosimilar, Whole mAb)	Catumaxomab	EpCAM;CD3E
GMP-Bios-INN-780	Anti-ERBB2;4-1BB therapeutic antibody (Pre-made Cinrebafusp alfa biosimilar, IG-GAMMA-4 -[LCN2]2 _KAPPA)	Cinrebafusp alfa	ERBB2;4-1BB
GMP-Bios-INN-845	Anti-CD3E;HER2 therapeutic antibody (Pre-made Ertumaxomab biosimilar,Whole mAb)	ertumaxomab	CD3E;HER2

Targeting multiple receptors

Bridging receptors is an obligate mechanism in which the binding of BsAbs to 2 receptors causes the activation or inhibition of each receptor. The co-activation or inhibition synergistically enhanced the biological effect of single antibody.

Cat No.	Products Name (INN Index)	INN name	Target
GMP-Bios-ab-007	Anti-CD274;TNFRSF9 therapeutic antibody (Pre-made Acasunlimab biosimilar,Bispecific mAb)	Acasunlimab	CD274;TNFRSF9
GMP-Bios-ab-021	Anti-EGFR;MET therapeutic antibody (Pre-made Amivantamab biosimilar,Bispecific mAb)	Amivantamab	EGFR;MET
GMP-Bios-ab-088	Anti-PDCD1;CTLA4 therapeutic antibody (Pre-made Cadonilimab biosimilar,Bispecific Mixed mAb and scFv)	Cadonilimab	PDCD1;CTLA4

Cat No.	Products Name (INN Index)	INN name	Target
GMP-Bios-ab-194	Anti-CD274;CTLA4 therapeutic antibody (Pre-made Erfonrilimab biosimilar,Bispecific Single Domains (VH-VH'-CH))	Erfonrilimab	CD274;CTLA4
GMP-Bios-ab-287	Anti-ICOS;PDCD1 therapeutic antibody (Pre-made Izuralimab biosimilar,Bispecific Mixed mAb and scFv)	Izuralimab	ICOS;PDCD1
GMP-Bios-ab-432	Anti-LAG3;CTLA4 therapeutic antibody (Pre-made Pavunalimab biosimilar,Bispecific Mixed mAb and scFv)	Pavunalimab	LAG3;CTLA4
GMP-Bios-ab-440	Anti-EGFR;LGR5 therapeutic antibody (Pre-made Petosemtamab biosimilar,Bispecific mAb)	Petosemtamab	EGFR;LGR5
GMP-Bios-ab-556	Anti-PDCD1;LAG3 therapeutic antibody (Pre-made Tebotelimab biosimilar,Bispecific scFv with Crossover)	Tebotelimab	PDCD1;LAG3
GMP-Bios-ab-631	Anti-CTLA4;PDCD1 therapeutic antibody (Pre-made Vudalimab biosimilar,Bispecific Mixed mAb and scFv)	Vudalimab	CTLA4;PDCD1
GMP-Bios-ab-667	Anti-PDCD1;ERBB2 therapeutic antibody (Pre-made Fidasimtamab biosimilar,Whole mAb)	Fidasimtamab	HER2;PD1
GMP-Bios-ab-679	Anti-PDCD1;CTLA4 therapeutic antibody (Pre-made Lorigerlimab biosimilar,Whole mAb)	Lorigerlimab	PDCD1;CTLA4
GMP-Bios-ab-701	Anti-CD40;TNFRSF9 therapeutic antibody (Pre-made Tecaginlimab biosimilar,Whole mAb)	Tecaginlimab	CD40;CD173
GMP-Bios-INN-836	Anti-CD19;CD137therapeutic antibody (Pre-made Tecaginlimab biosimilar,Whole mAb)	ensomafusp alfa	CD19;41BB ligand (fusized protein)
GMP-Bios-INN-981	Anti-CD11;CD18 therapeutic antibody (Pre-made Acasunlimab biosimilar,Bispecific mAb)	Rovelizumab	CD11;CD18

ligand redundancy

In addition to bind to the receptors, targeting redundancy for cytokines or angiogenesis factors represents an area of interest for BsAbs.

Cat No.	Products Name (INN Index)	INN name	Target
GMP-Bios-ab-145	Anti-DLL4;VEGFA therapeutic antibody (Pre-made Dilpacimab biosimilar,Bispecific mAb)	Dilpacimab	DLL4;VEGFA
GMP-Bios-ab-204	Anti-VEGFA;ANGPT2 therapeutic antibody (Pre-made Faricimab biosimilar,Bispecific mAb)	Faricimab	VEGFA;ANGPT2
GMP-Bios-ab-282	Anti-IGF1R;ERBB3 therapeutic antibody (Pre-made Istiratumab biosimilar,Bispecific Mixed mAb and scFv)	Istiratumab	IGF1R;ERBB3
GMP-Bios-ab-331	Anti-IL1A;IL1B therapeutic antibody (Pre-made Lutikizumab biosimilar,Bispecific Dual Variable Domain IG)	Lutikizumab	IL1A;IL1B
GMP-Bios-ab-369	Anti-DLL4;VEGFA therapeutic antibody (Pre-made Navicixizumab biosimilar,Bispecific mAb)	Navicixizumab	DLL4;VEGFA
GMP-Bios-ab-478	Anti-IL17A;TNFA therapeutic antibody (Pre-made Remtolumab biosimilar,Bispecific Dual Variable Domain IG)	Remtolumab	IL17A;TNFA
GMP-Bios-ab-492	Anti-IL13;IL4 therapeutic antibody (Pre-made Romilkimab biosimilar,Bispecific Dual Variable Domain IG)	Romilkimab	IL13;IL4
GMP-Bios-ab-568	Anti-TNFSF13B;IL17A therapeutic antibody (Pre-made Tibulizumab biosimilar,Bispecific Mixed mAb and scFv)	Tibulizumab	TNFSF13B; IL17A
GMP-Bios-ab-612	Anti-ANGPT2;VEGFA therapeutic antibody (Pre-made Vanucizumab biosimilar,Bispecific mAb)	Vanucizumab	ANGPT2;VEGFA
GMP-Bios-INN-793	Anti- NT5E; TGFBR2 therapeutic antibody (Pre-made Vanucizumab biosimilar,Bispecific mAb)	dalutrafusp alfa	NT5E; TGFBR2

Biparatopic bsAbs

Instead of targeting two different proteins, bsAbs may be designed to simultaneously bind to two non-overlapping epitopes on the same target. Biparatopic targeting builds on increasing binding strength through antigen crosslinking and aggregation, thereby mimicking effects observed for antibody mixtures and polyclonal antibodies. Biparatopic bsAbs are therefore essentially a combinatorial concept.

Cat No.	Products Name (INN Index)	INN name	Target
GMP-Bios-ab-023	Anti-ERBB2 (Domain II);ERBB2 (Domain IV) therapeutic antibody (Pre-made Anbenitamab biosimilar,Bispecific mAb)	Anbenitamab	ERBB2 (Domain II);ERBB2 (Domain IV)
GMP-Bios-ab-639	Anti-ERBB2;ERBB2 therapeutic antibody (Pre-made Zanidatamab biosimilar,Bispecific mAb)	Zanidatamab	ERBB2;ERBB2
GMP-Bios-INN-813	Anti-VEGF;VEGF;fused CR1 therapeutic antibody (Pre-made Efdamrofusp alfa biosimilar,Bispecific mAb)	Efdamrofusp alfa	VEGF (Domain II); VEGF (Domain III);fused CR1

Cofactor mimetics

BsAbs can also be designed as a scaffold or cofactor linking enzyme and substrate together. One of the applications is the BsAbs used as a substitution of a critical clotting factor in the treatment of hemophilia.

Cat No.	Products Name (INN Index)	INN name	Target
GMP-Bios-ab-177	Anti-F9;F10 therapeutic antibody (Pre-made Emicizumab biosimilar,Bispecific mAb)	Emicizumab	F9;F10

Piggyback approaches

Exploit the first binding specificity of a BsAb as a transport modality for the second specificity are named the "piggyback" approaches. To cross the blood-brain barrier, one binding arm of the BsAbs are designed to target the transferrin receptor (TfR). The human serum albumin (HSA) targeting domain are used to extent the half-life of BsAbs, especially to BsAbs without Fc, for example the tandem ScFvs or VHHs. In addition, the piggyback approaches are also been used in promoting the degradation of pathogens.

Cat No.	Products Name (INN Index)	INN name	Target
GMP-Bios-ab-251	Anti-RSV gpF therapeutic antibody (Pre-made Gontivimab biosimilar,Bispecific Single Domains (VH-VH'-VH'))	Gontivimab	RSV gpF
GMP-Bios-ab-253	Anti-PcrV type III secretion system;Polysaccharide synthesis locus (Pseudomonas) therapeutic antibody (Pre-made Gremubamab biosimilar,Bispecific mAb)	Gremubamab	PcrV type III secretion system; Polysaccharide synthesis locus (Pseudomonas)
GMP-Bios-ab-281	Anti-ADAMTSL5;ALB therapeutic antibody (Pre-made Isecarosmab biosimilar,Bispecific Single Domains (VH-VH'))	Isecarosmab	ADAMTSL5;ALB
GMP-Bios-ab-419	Anti-TNFA;ALB therapeutic antibody (Pre-made Ozoralizumab biosimilar,Bispecific Single Domains (VH-VH'-VH))	Ozoralizumab	TNFA;ALB
GMP-Bios-ab-625	Anti-IL6R;ALB therapeutic antibody (Pre-made Vobarilizumab biosimilar,Bispecific Single Domains (VH-VH'))	Vobarilizumab	IL6R;ALB
GMP-Bios-INN-880	Anti-ALB;IL17A/IL17 Therapeutic Antibody (Pre-Made Izokibep Biosimilar, Bispecific, Anti-FDAHT/HSA/PRO0883/PRO0903/PRO1341;CTLA-8/CTLA 8A Antibody)	Izokibep	ALB; IL17A
GMP-Bios-INN-996	Anti-ALB;IL17A/IL17;IL17F Therapeutic Antibody (Pre-Made Sonelokimab Biosimilar, Bispecific, Anti-FDAHT/HSA/PRO0883/PRO0903/PRO1341;CTLA-8/CTLA8/IL-17A/ILA17;CANDF6/ML-1/ML1 Antibody)	Sonelokimab	IL17A;ALB; IL17F

2. Introduction about bispecific antibodies (BsAbs)

Bispecific antibodies (BsAbs) are designed to bind two different epitopes or antigens, which leads to multiple mechanistic functions with synergistic effects. The attractive feature is their potential for novel functionalities, which do not exist in mixtures of the parental or reference antibodies. Till now, more than 200 BsAb-based clinical trails have been registered on clinicaltrails.org and 4 BsAbs (with one withdraw) have been granted FDA approval. The promising future makes BsAbs attracting more attentions.

The connecting of two specificities within one BsAb can be exploited for novel therapeutic concepts. The mostly applications of BsAbs are recruiting effector cells to the target cells, which are regarded as the immune cell engagers. The redirection of the cytotoxic effector cells (T and NK cells) to the targeting cancer cells by BsAbs physically link them together and activate the effector cells to eliminate the target ones. In addition, the BsAbs can also be used to link two molecules together to make the therapeutic effects such as the dual inhibition of immune checkpoints, the conditionally activate a growth factor receptor for diabetes treatment and the replacement of natural bridge molecules such as the coagulation factor VIII. More innovative designs of BsAbs can be achieved in the future.

To accelerate the development of BsAbs, Genemedi offers the high quality, premade benchmark BsAbs for researchers. The biosimilars are expressed by mammalian cell line and used for biological drug discovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

3. Formats of bispecific antibodies (BsAbs)

Many formats have been developed for BsAb generation as listed in the following table.

Format	Schematic structure	Description	Example BsAb	Trademark	Company
tandem VHH		Tandem VHH fragment-based BsAb	N/A		
tandem scFv		Tandem ScFv fragment-based BsAb	AMG330	BiTE™	Amgen
Dual-affinity re-targeting antibody		Tandem domain-exchanged Fv (can also be used to fuse with Fc domain to create whole Abs)	Flotetuzumab	DART™	Macrogenics
Diabody		dimer of single-chain Fv (scFv) fragment	vixtimotamab	ReSTORE™	Amphivena Therapeutics
(scFv)2-Fab		a Fab domain and two scFv domains bind	A-337	ITab™	Generon/EVIV E Biotech

Format	Schematic structure	Description	Example BsAb	Trademark	Company
Rat–mouse hybrid IgG		Full-size IgG-like half antibodies from two different species	Catumaxomab	Triomab™	Trion Pharma
Hetero heavy chain, Common light chain		Hetero heavy chain, Common light chain	Emicizumab	ART-Ig™	Genentech/ Chugai/Roche
Controlled Fab arm exchange		Recombin the parental half antibodies	JNJ-64007957	Duobody™	Genmab/ Janssen
Hetero H, forced HL IgG1		KIH technology for heterodimerization of 2 distinct H chains, replacing the native disulfide bond in one of the CH1-CL interfaces with an engineered disulfide bond to enhance the cognate of H and L paring	MEDI5752	DuetMab™	MedImmune/ AstraZeneca
cH IgG1		Identical heavy chains; 2 different light chains: one kappa (κ) and one lambda (λ)	NI-1701	κλ body™	Novimmune SA
Hetero H, CrossMab		KIH technology; domain crossover of immunoglobulin domains in the Fab region	Vanucizumab	CrossMab™	Roche
scFv-Fab IgG		Fab-Fc; ScFv-Fc	Vibecotamab; M802	Xmab™ (the engineered Fc to enhance the generation of heterodimeric Fc); YBODY™	Xencor/Amgen; YZYBio
VH1-VH2-CH1-Fc1 (G1) x VL2-VL1-CL -Fc2(G1)		2 binding motif in one half antibody	SAR440234	CODV-Ig™	Sanofi

Format	Schematic structure	Description	Example BsAb	Trademark	Company
VL1-CL1-VH2-CH2-Fc x VH1-CH1 x VL2-CL2		2 binding motif in one half antibody	EMB-01	FIT-Ig™	EPIMAB BIOTHERAPEUTICS
VH-1-TCR Cα x VL-1-TCR Cβ; VH-2-CH-2-Fc x VL-2-CL-2		KIH technology; TCR Cα/Cβ is used to substitute the CH1 and CL domain in one arm		WuXibody™	WuXi Biologics
C-terminal linker of Fc		Link the other molecules at the C-terminal of Fc	APVO442	ADAPTIR-FLEX™	Aptevo Therapeutics
Fc antigen binding site		2 natural binding sites; 2 additional binding sites in the Fc loop	FS118	mAb^2	F-star Therapeutics

4. Bispecific Antibody Development Programs Guidance for Industry by FDA

FDA set up the guidance for the development of BsAbs. The link and PDF files are listed below.

Bispecific Antibody Development Programs Guidance for Industry

About GeneMedi

We develop solutions for the therapeutics and diagnostics industry.

GENEMEDI
Innovative Solution
for Therapeutics & Diagnostics Industry

About GMole™

GMolecule-Innovative capabilities in molecular entity discovery and application development.

GMolecule is the capabilities derived from insight and expertise of Gene & Biologics molecular entity discovery and development. Our QbD process is combined and optimized with intelligent design, smart discovery, rational development, and State-of-the-Art manufacturing (D&D&D&M). Data management is separated independently for high-quality data certification. The modalities and facilities of GMolecule are including antibodies, recombinant protein, and multiple types of gene therapy vectors and delivery vehicles (AAV, lentivirus, virus-like particle(VLP), etc.).

About GTU&GDU

GTU&GDU, GeneMedi Therapeutics Unit & GeneMedi Diagnostics Unit, are GM's 2 unique product-solution units for the industry of therapeutics or diagnostics. Since the insight from GM's unique in-house database-GM target/biomarkers and diseases database, GM empowers self-capabilities for application development to develop more effective products and solutions to meet the needs of the therapeutics and diagnostics industry.

About GeneMedi ITD

ITD is GeneMedi's target-insight database that connects human indications/diseases/conditions with associated targets/biomarkers in diagnostics, therapeutics, and prognostics. ITD is a data-driven artificial intelligent system that learns from literature and in-house wet-dry exploration with closed-loop design. GeneMedi ITD target-insight system robustly improves the development efficiency for therapeutics and diagnostics industry solutions.

BGM X

Passion,Innovation,Pioneer,Explorer

With years of modalities discovery insight and expertise in the pharmaceutical industry, GeneMedi has developed innovative BGM-X™ Engine for big data-driven scientific discovery and industrial development in modalities of biologics and gene therapeutics.

Taurus

TAURUS™ PLATFORM FOR DIFFICULT TARGETS ANTIBODY DISCOVERY

GeneMedi's Taurus™-Antibody Discovery Platform is to achieve **T**ough **A**ntigen **U**nique-epitope **R**ecognized with **U**nique **S**mart-immunogen strategy.

LIBRA

LIBRA™-ANTIBODY ENGINEERING PLATFORM FOR ANTIBODY HUMANIZATION, MATURATION, AND RATIONAL EVOLUTION

LIBRA is developed with the characteristics: **L**ight, **I**ntelligent, **B**alanced, **R**ational, and **A**lgorithm-driven.

G-NEXT

NOVEL AAV DISCOVERY & RATIONAL-EVOLUTION PLATFORM

GeneMedi's **N**ovel **E**volution-**X** **T**echnology for discovery of next generation of AAV. X refers to the exploring of AAV for more possibilities with GeneMedi's innovational strategies.

GENEMEDI

Innovation In Gene Therapy & Biologics

SOCAIL MEDIA

Email: support@genemedi.net | sales@genemedi.net

Telephone: +86-21-50478399 **Fax:** 86-21-50478399

Address: 6th Floor, Building No.2, KangXin Road 3377,Shanghai, China

Leave your message, we will reply in 1 day: www.genemedi.net/contact